跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
在 國立成功大學 搜尋內容
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
查看斯高帕斯 (Scopus) 概要
杜 業豐
Doctor
內科部
電子郵件
nckuhyfdu
gmail
com
h-index
220
引文
8
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2013
2026
每年研究成果
概覽
指紋
網路
研究成果
(15)
類似的個人檔案
(6)
指紋
查看啟用 Ye-Fong Du 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Hedgehog Proteins
50%
Continuous Glucose Monitoring
50%
Noninsulinoma Pancreatogenous Hypoglycemia Syndrome
50%
BMI Trajectory
50%
Social Apps
50%
Communication Apps
50%
Basal Insulin
50%
Longitudinal Population-based Cohort
50%
Long-acting Insulin Analog
50%
Ultra-long-acting Insulin
50%
Intravenous Insulin
50%
Economic Burden
50%
Longitudinal Analysis
50%
Type 1 Diabetes Mellitus (T1DM)
50%
Type I Diabetes
50%
Ketosis
40%
Calcium Assay
37%
Total Pancreatectomy
25%
Myocardial Infarction
25%
Ischemic Heart Disease
25%
Kidney Transplant
25%
Event Year
25%
Continuous Glucose Monitor
20%
Mean Amplitude of Glycemic Excursions
16%
Fasting Test
12%
Post-bariatric Hypoglycemia
12%
Neuroglycopenia
12%
Diabetes Education
12%
Reducing Blood Glucose
12%
Distress Score
12%
Islet Cells
12%
Endogenous Hyperinsulinism
12%
Cost-effective Intervention
12%
Asian Population
12%
Acute Complications
12%
Health Care Costs
12%
Diabetic Neuropathy
12%
Associated Complications
12%
Diabetes
12%
Event Occurrence
12%
End-stage Renal Disease
12%
Cardiovascular Mortality
12%
Fatal Complication
12%
Early Prevention
12%
Hyperglycemia and Hypoglycemia
12%
Diabetic Foot
12%
Peripheral Vascular Disease
12%
Hemorrhagic Stroke
12%
Taiwan National Health Insurance Research Database
12%
Nephropathy
12%
Pharmacology, Toxicology and Pharmaceutical Science
Long Acting Insulin
92%
Biological Marker
75%
Insulin Analog
58%
Insulin Dependent Diabetes Mellitus
58%
Ketoacidosis
50%
Hedgehog
50%
Spontaneously Hypertensive Rat
50%
Diabetic Ketoacidosis
50%
Fatty Liver
50%
Insulin Resistance
50%
Fenretinide
50%
Peroxisome Proliferator Activated Receptor Gamma
50%
Diseases
28%
Hyperglycemia
26%
Alanine Aminotransferase
25%
C Reactive Protein
25%
High Density Lipoprotein Cholesterol
25%
Nonalcoholic Fatty Liver
25%
Triacylglycerol
25%
Lipopolysaccharide
22%
Heart Infarction
20%
Ischemic Heart Disease
20%
Peroxisome Proliferator Activated Receptor
18%
Glucotoxicity
16%
Mild Hepatic Impairment
16%
Diabetic Complication
10%
Hypoglycemia
10%
End Stage Renal Disease
10%
Cerebrovascular Disease
10%
Peripheral Vascular Disease
10%
Cardiovascular Disease
10%
Diabetes Mellitus
10%
Brain Hemorrhage
10%
Neuropathy
10%
Kidney Disease
10%
Cytokine
9%
Inflammation
9%
Peroxisome Proliferator Activated Receptor Antagonist
9%
Dicarbonate
8%
Pharmacokinetic
8%
Medicine and Dentistry
Long Acting Insulin
100%
Glycemic Control
66%
Insulin Dependent Diabetes Mellitus
58%
Patient with Type 2 Diabetes
50%
Ketoacidosis
50%
Placebo
50%
Diabetic Ketoacidosis
50%
Rebound
50%
Hemoglobin A1c
50%
Glycemic
50%
Health Care Cost
50%
Human Insulin
41%
Recombinant Human Insulin
41%
Hyperglycemia
22%
Complementary Therapy
16%
Oral Antidiabetic Agent
16%
Behavioral Modification
12%
Ischemic Heart Disease
11%
Myocardial Infarction
11%
Kidney Graft
11%
Neuroglycopenia
10%
Blood Glucose
8%
Sodium Bicarbonate
8%
Pharmacokinetic
8%
Insulin Treatment
8%
Case Presentation
8%
Complication of Diabetes
5%
Hypoglycemia
5%
Cerebrovascular Disease
5%
Cardiovascular System
5%
Diabetes Mellitus
5%
Cardiovascular Disease
5%
End Stage Renal Disease
5%
Peripheral Vascular Disease
5%
Neuropathy
5%
Diabetes
5%
Cerebral Hemorrhage
5%
Nephropathy
5%
